Avid Bioservices Inc (CDMO)

[EYEBUYSTOX]

I speculated that there may be an update from the HER2-Neg breast cancer IST that reported 85% ORR in 13 patients at last year's ASCO. The trial completed enrollment in April 2013 so they will have complete 1 year survival data for the entire 14 patient data set.

7, possibly 8 of the 14 patients were triple negative so a detailed analysis of ORR and OS for that subset is of particular interest to me considering the high recurrence of the disease in the liver and lungs. And if those PRs turned into CRs we could be looking at a game-changer.

We know taxane based chemo has great synergy with bavituximab so if the trends from last year continue we're in good shape to move the trial forward possibly even with an expedited pathway IMO.

Other than that I'm not really expecting much from ASCO.